Cytarabine IT is named as an intervention in 2 current clinical trials in our Canada and Australia registers. 2 are recruiting patients now. The most common phase is Phase EARLY_PHASE1. The sponsor with the most trials is C17 Council (1). The most-studied condition is CNS Embryonal Tumor.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
NCT06942039 · ClinicalTrials.gov ↗ · CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor
|
Phase EARLY_PHASE1 | Recruiting | C17 Council | Canada |
|
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
NCT05476770 · ClinicalTrials.gov ↗ · Hematologic Malignancy, AML, ALL
|
Phase 1 | Recruiting | Therapeutic Advances in Childhood Leukemia Consortium | Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| C17 Council | 1 |
| Therapeutic Advances in Childhood Leukemia Consortium | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Australia | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Canada and Australia registers name Cytarabine IT as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in Canada and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
C17 Council (1) and Therapeutic Advances in Childhood Leukemia Consortium (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cytarabine IT works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cytarabine IT works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cytarabine IT (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.